Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 3 - License / Supplier Agreement (Details Textual)

Note 3 - License / Supplier Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended	4 Months Ended
	Apr. 28, 2023	Mar. 30, 2023	Feb. 28, 2023	Oct. 29, 2018	Dec. 31, 2019	Mar. 31, 2023	Jun. 17, 2015
Contractual Obligation Development Expense					$ 81,500
Contractual Obligation, Commercial Expense					$ 151,000
Stock Issued During Period, Value, License Expense						$ 1,230
AnnJi [Member]
License Agreement, Purchase Consideration			$ 3,000
Acquired License Payable Within 180 Days			1,000
Maximum Reimbursement Amount In Connection With Product Clinical Trial			10,800
Maximum Reimbursement Amount In Connection With Certain Development Milestones			14,500
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone			27,500
Maximum Reimbursement Amount Upon Achievement of Sales Milestone			$ 165,000
Stock Issued During Period, Shares, License Expense (in shares)		831,618
Stock Issued During Period, Value, License Expense		$ 900
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares)			276,652
Stock Issuable During Period, Value, Upon Enrollment of Patient			$ 300
AnnJi [Member] \| Minimum [Member]
Sales Milestone Required for Maximum Reimbursement			75,000
Annual Sale Threshold for Royalty Payment			50,000
AnnJi [Member] \| Maximum [Member]
Sales Milestone Required for Maximum Reimbursement			750,000
Annual Sale Threshold for Royalty Payment			$ 300,000
AnnJi [Member] \| Subsequent Event [Member]
Payments to Acquire License	$ 2,000
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments							$ 3,000
Baergic Licenses [Member] \| CCHMC [Member]
Percentage of Equity Fee					5.00%
Polpharma [Member]
Payments to Acquire in Process Research and Development				$ 2,000
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Upfront Payment [Member]
Payments to Acquire in Process Research and Development							2,000
Percentage of Equity Fee					20.00%
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Additional Payment [Member]
Payments to Acquire in Process Research and Development					$ 1,000		$ 1,000
Baergic Licenses [Member] \| Upfront Payment [Member] \| CCHMC [Member]
Payments to Acquire in Process Research and Development					200
Baergic Licenses [Member] \| Upfront Payment [Member] \| AZERBAIJAN
Payments to Acquire in Process Research and Development					$ 3,000
AnnJi [Member]
Right to Sell Common Stock, Price Per Share (in dollars per share)			$ 2.10